Encorton

DRUG4 trials

Sponsors

Sanofi-Aventis Recherche & Developpement, Medical University Of Warsaw, Crinetics Pharmaceuticals Inc.

Conditions

Children primary nephropathy IgAMusculoskeletal diseasesMyocarditisinflammatory cardiomyopathy• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Phase 2

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

Not yet recruitingCTIS2025-522648-42-01

Crinetics Pharmaceuticals Inc.• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Target: 25Updated: 2026-09-29

Phase 3

SABINE - The efficacy and Safety of delayed-release Budesonide in children with primary IgA nephropathy - a multicenter, interventional phase III, randomized, placebo-controlled, double-blind study.

Not yet recruitingCTIS2024-518759-45-00

Medical University Of WarsawChildren primary nephropathy IgA

Target: 120Updated: 2025-11-25

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

Not yet recruitingCTIS2024-511296-15-00

Sanofi-Aventis Recherche & DeveloppementMusculoskeletal diseases

Target: 80Updated: 2026-06-16

Phase 4

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus-negative myocarditis or inflammatory cardiomyopathy (IMPROVE-MC).

RecruitingCTIS2024-517484-23-00

Medical University Of Warsawinflammatory cardiomyopathy, Myocarditis

Start: 2022-07-26Target: 100Updated: 2024-11-05